AB-101-05

A Phase 2a, open-label study to evaluate the safety and efficacy of AlloNK® (allogeneic NK-cell therapy derived from umbilical cord blood) in combination with rituximab in relapses of B-cell-dependent rheumatic diseases

Condition studied : Systemic sclerosis, Rheumatoid arthritis, Idiopathic inflammatory myopathies
Treatment : Combined administration of AlloNK® and Rituximab
Inclusion criteria :

– Have been diagnosed with systemic sclerosis, inflammatory myopathy, or Gougerot-Sjögren syndrome.
– Have active disease (e.g. moderate to severe skin sclerosis for cutaneous sclerosis; or painful and swollen joints for rheumatoid arthritis)

Exclusion criteria :

– Severe cardiac or pulmonary involvement
– Having previously been treated with haematopoietic stem cell autologous transplantation or CAR-T cells.

Sponsor : Artiva
Principal Investigator : Pr. Christian Jorgensen
: NCT06991114 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | ClinicalTrials.gov
Investigator
Pr. Christian Jorgensen
Director
Rechercher sur le site